Insmed, Inc. (NASDAQ:INSM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have earned an average rating of “Moderate Buy” from the twenty-five ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, twenty-three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $211.8636.

Several equities research analysts have issued reports on INSM shares. Truist Financial dropped their price objective on Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Bank of America lifted their price objective on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, June 10th. Barclays lifted their price objective on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st.

Insmed Stock Performance

Insmed stock opened at $95.70 on Tuesday. The stock’s 50 day moving average price is $117.97 and its 200 day moving average price is $147.47. The firm has a market capitalization of $20.74 billion, a PE ratio of -16.64 and a beta of 0.79. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. Insmed has a one year low of $90.39 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.Insmed’s revenue for the quarter was up 229.7% on a year-over-year basis. During the same period in the previous year, the company posted ($1.42) EPS. As a group, sell-side analysts expect that Insmed will post -2.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 2,159 shares of Insmed stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $220,800.93. Following the sale, the insider directly owned 39,454 shares in the company, valued at $4,034,960.58. The trade was a 5.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 7,605 shares of Insmed stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $777,763.35. Following the sale, the chief executive officer owned 265,432 shares in the company, valued at $27,145,730.64. This represents a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 149,783 shares of company stock valued at $22,902,672 over the last 90 days. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its position in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. Kingsview Wealth Management LLC raised its position in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares during the period. Choreo LLC raised its position in shares of Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 69 shares during the period. Finally, ORG Partners LLC raised its position in Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 74 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.